- Hemostemix (HEM) has evolved its patented Automated Cell Therapy System (ACTS)
- It is designed to scale its autologous stem cell therapy processes by leveraging robotic material handling and parallel-processing efficiencies, duplicating the manual methods of angiogenic cell precursor (ACP-01) production
- The production plan calls for development through Q3 of 2023 and site acceptance testing of the ACTS prototype in Q4, 2023
- Hemostemix Inc. (HEM) opened trading at C$0.14
Hemostemix (HEM) has evolved its patented Automated Cell Therapy System (ACTS).
The Hemostemix ACTS is designed to scale its autologous stem cell therapy processes by leveraging robotic-material-handling and parallel-processing efficiencies, duplicating the manual methods of angiogenic cell precursor (ACP-01) production.
ACTS will scale ACP-01 production to generate high-quality, safe, and efficacious patient-derived stem cell therapeutics.
The proof of principle system will perform the core synergetic cell precursor isolation, its differentiation into ACP-01, and its harvesting into ready-to-use syringes that are couriered to the patient’s physician after meeting batch release criteria. The production plan calls for development through Q3 of 2023 and site acceptance testing of the ACTS prototype in Q4.
Pete Pavlin, P.Eng., Vice-President Operations, stated, “Having reviewed available biologics scaling technologies and 3rd party integration teams in the marketplace, we have evolved a project execution plan that scales ACP-01 production to meet global demand.”
Hemostemix is a clinical-stage biotechnology company. The company’s principal business activity is to develop, manufacture, and commercialize blood-derived cell therapies for medical conditions.
Hemostemix Inc. (HEM) opened trading at C$0.14.
